Competing Pathways in the Photo-Favorskii Rearrangement and Release of Esters: Studies on Fluorinated <i>p</i>-Hydroxyphenacyl-Caged GABA and Glutamate Phototriggers
作者:Kenneth Stensrud、Jihyun Noh、Karl Kandler、Jakob Wirz、Dominik Heger、Richard S. Givens
DOI:10.1021/jo900139h
日期:2009.8.7
Three new trifluoromethylated p-hydroxyphenacyl (pHP)-caged γ-aminobutyric acid (GABA) and glutamate (Glu) derivatives have been examined for their efficacy as photoremovable protecting groups in aqueous solution. Through the replacement of hydrogen with fluorine, e.g., a m-trifluoromethyl or a m-trifluoromethoxy versus m-methoxy substituents on the pHP chromophore, modest increases in the quantum
[EN] PYRIMIDINE INHIBITORS OF KINASE ACTIVITY<br/>[FR] INHIBITEURS PYRIMIDINES DE L'ACTIVITÉ KINASE
申请人:ABBOTT LAB
公开号:WO2010138576A1
公开(公告)日:2010-12-02
The present invention relates to compounds of formula (I) or pharmaceutical acceptable salts or solvates thereof, wherein G1, R2, R3, R4, R5, n, p, q, Ar1, and Ar2 are defined in the description. The present invention relates also to methods of making said compounds, and compositions comprising said compounds which are useful for inhibiting kinases such as IGF-IR.
Novel N-hydroxyamide derivatives are disclosed. These N-hydroxyamide derivatives inhibit UPD-3-O—(R-3-hydroxymyristoyl)-N-acetylglucosamine deacetylase, an enzyme present in gram negative bacteria and are therefore useful as antimicrobials and antibiotics. Methods of synthesis and of use of the compounds are also disclosed.
The present invention relates to compounds of formula (I) or pharmaceutical acceptable salts or solvates thereof,
wherein G
1
, R
2
, R
3
, R
4
, R
5
, n, p, q, Ar
1
, and Ar
2
are defined in the description. The present invention relates also to methods of making said compounds, and compositions comprising said compounds which are useful for inhibiting kinases such as IGF-1R.
SUBSTITUTED 3,7-DIHYDRO-1H-PURINE-2,6-DIONES AND USE THEREOF
申请人:invIOs GmbH
公开号:EP4389749A1
公开(公告)日:2024-06-26
The present invention relates to 3,7,8-trisubstituted 3,7-dihydro-1/-/-purine-2,6-dione compounds also named as 3,7,8-trisubstituted xanthine compounds of general formula (I) or pharmaceutically acceptable salts thereof.
The invention further relates to pharmaceutical compositions comprising such compounds as well as the use of the compounds or pharmaceutical compositions as medicaments, especially in methods for the treatment or prophylaxis of a neoplastic and/or infectious disease and in vitro methods.
These compounds activate immune cells, in particular T-cells such as CD4+ and CD8+ cells.